A Combined Drug Treatment That Reduces Mitochondrial Iron and Reactive Oxygen Levels Recovers Insulin Secretion in...

Area of Science:

• Cell Biology
• Endocrinology
• Metabolic Diseases

Background:

• Pancreatic beta-cell failure and decreased insulin secretion are central to diabetes, obesity, and cancer.
• Hereditary iron overload conditions like Wolfram syndrome type 2 (WFS-T2) link iron metabolism to beta-cell failure.
• Reactive oxygen species (ROS) are implicated in beta-cell dysfunction.

Purpose of the Study:

• To investigate the role of NAF-1 (encoded by CISD2) in pancreatic beta-cell function and insulin secretion.
• To explore the impact of NAF-1 suppression on mitochondrial and ER structure and function.
• To identify potential therapeutic strategies for WFS-T2 by targeting iron and ROS levels.

Main Methods:

• Utilized NAF-1-repressed INS-1E pancreatic cells to model WFS-T2.
• Assessed insulin secretion, mitochondrial and ER structure/function.
• Administered iron chelators (deferiprone), glutathione precursors (N-acetyl cysteine), and ferroptosis inhibitors (ferrostatin-1).
• Measured mitochondrial labile iron and ROS levels.

Main Results:

• NAF-1 repression inhibited insulin secretion and impaired mitochondrial/ER structure and function.
• Combined deferiprone and N-acetyl cysteine treatment repaired cellular structures, reduced iron/ROS, and restored insulin secretion.
• Ferrostatin-1 treatment decreased ROS and improved cell growth in NAF-1 repressed cells.
• Findings indicate NAF-1 suppression induces ferroptosis-like features.

Conclusions:

• Suppressed NAF-1 expression contributes to pancreatic beta-cell failure via ferroptosis-like mechanisms.
• Reducing mitochondrial iron and ROS levels presents a potential therapeutic approach for WFS-T2.
• Targeting iron metabolism and oxidative stress may ameliorate beta-cell dysfunction in specific genetic conditions.